Certain 1,4-Disubstituted Aromatic Piperidines and Piperazines with Extreme Selectivity for the Dopamine D4 Receptor Interact with a Common Receptor Microdomain

We previously demonstrated that, in the D4 dopamine receptor, the aromatic microdomain that spans the interface of the second and third transmembrane segments influences the high-affinity interactions with the D4-selective ligand L750,667 [3-{[4-(4-iodophenyl) piperazin-1-yl]methyl}-1H-pyrrolo[2,3-b]pyridine] and the D2-selective ligands methylspiperone, aripiprazole, and its congener OPC4392 [7-[3-(4-(2,3-dimethylphenyl) piperazinyl) propoxy] 2-(1H)-quinolinone] (Schetz et al., 2000). Here we tested a variety of 1,4-disubstituted aromatic piperidines/piperazines (1,4-DAPs) with different subtype selectivities and functional properties against a panel of D4 receptor mutations in the aromatic microdomain to ascertain whether these ligands recognize this common site. Mutant D4 receptors were constructed by substituting the nonconserved amino acid(s) from the corresponding locations in the D2 receptor. The D4-L2.60W, D4-F2.61V, and D4-LM3.28-3.29FV substitutions result in alterations of the relative position of members of the aromatic microdomain. From these results and molecular models of the ligand-receptor complexes, we conclude that 9 of the 11 D4-selective 1,4-DAPs, including L750,667, have a common pattern of ligand-receptor recognition that depends upon favorable interactions with the phenylalanine at position 2.61 (D4-F2.61V, 20-96-fold decrease). Like methylspiperone, aripiprazole, and OPC4392, the two D4-selective 1,4-DAPs that are insensitive to the D4-F2.61V mutation are sensitive to aromatics at position 2.60 (D4-L2.60W, 7-20-fold increase), and they all have longer spacer arms that permit their tethered aromatics to adopt alternative orientations in the binding-site crevice. All 11 of the D4-selective 1,4-DAPs were sensitive to the D4-LM3.28-3.29FV mutation (13-494-fold decrease) but not the moderately D2-selective methylspiperone. The inferences suggest that subtype selectivity involves two different modes of interaction with the microdomain for the D4-selective 1,4-DAPs and a third mode for D2-selective 1,4-DAPs.

[1]  D. Sibley,et al.  Nonconserved residues in the second transmembrane-spanning domain of the D(4) dopamine receptor are molecular determinants of D(4)-selective pharmacology. , 2000, Molecular pharmacology.

[2]  C. Gallen,et al.  Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial , 2004, Biological Psychiatry.

[3]  D. Donnelly-roberts,et al.  Dopamine D4 ligands and models of receptor activation: 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole and related heteroarylmethylarylpiperazines exhibit a substituent effect responsible for additional efficacy tuning. , 2004, Journal of medicinal chemistry.

[4]  B. Sommer,et al.  NGD 94-1 as an agonist at human recombinant dopamine D4.4 receptors expressed in HEK293 cells. , 1999, European journal of pharmacology.

[5]  J. Javitch,et al.  Mechanisms of inverse agonism of antipsychotic drugs at the D2 dopamine receptor: use of a mutant D2 dopamine receptor that adopts the activated conformation , 2001, Journal of neurochemistry.

[6]  Harel Weinstein,et al.  Three-dimensional representations of G protein-coupled receptor structures and mechanisms. , 2002, Methods in enzymology.

[7]  Alexander D. MacKerell,et al.  All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.

[8]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[9]  J. Ballesteros,et al.  Electrostatic and aromatic microdomains within the binding-site crevice of the D2 receptor: contributions of the second membrane-spanning segment. , 1999, Biochemistry.

[10]  D. B. Duignan,et al.  Synthesis, SAR and pharmacology of CP-293,019: a potent, selective dopamine D4 receptor antagonist. , 1998, Bioorganic & medicinal chemistry letters.

[11]  H. Weinstein,et al.  Molecular basis of partial agonism: orientation of indoleamine ligands in the binding pocket of the human serotonin 5-HT2A receptor determines relative efficacy. , 2003, Molecular Pharmacology.

[12]  J. Ballesteros,et al.  [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .

[13]  J. Ballesteros,et al.  Dopamine D4/D2 receptor selectivity is determined by A divergent aromatic microdomain contained within the second, third, and seventh membrane-spanning segments. , 1999, Molecular pharmacology.

[14]  A. Getson,et al.  The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group. , 1997, Archives of general psychiatry.

[15]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2000, Science.

[16]  B. Sommer,et al.  The agonist activities of the putative antipsychotic agents, L‐745,870 and U‐101958 in HEK293 cells expressing the human dopamine D4.4 receptor , 1998, British journal of pharmacology.

[17]  David R. Sibley,et al.  Interactions of the Novel Antipsychotic Aripiprazole (OPC-14597) with Dopamine and Serotonin Receptor Subtypes , 1999, Neuropsychopharmacology.

[18]  H. Akil,et al.  Site-directed mutagenesis of the human dopamine D2 receptor. , 1992, European journal of pharmacology.

[19]  Robert P. Millar,et al.  Functional Microdomains in G-protein-coupled Receptors , 1998, The Journal of Biological Chemistry.

[20]  M. Piercey,et al.  Pharmacological characterization of U-101387, a dopamine D4 receptor selective antagonist. , 1996, The Journal of pharmacology and experimental therapeutics.

[21]  H. V. Van Tol,et al.  The dopamine D(4) receptor: one decade of research. , 2000, European journal of pharmacology.

[22]  M. Low,et al.  The dopamine D4 receptor is essential for hyperactivity and impaired behavioral inhibition in a mouse model of attention deficit/hyperactivity disorder , 2004, Molecular Psychiatry.

[23]  J. Ballesteros,et al.  A cluster of aromatic residues in the sixth membrane-spanning segment of the dopamine D2 receptor is accessible in the binding-site crevice. , 1998, Biochemistry.

[24]  J. Lusher,et al.  Dopamine D4 receptor gene (DRD4) is associated with Novelty Seeking (NS) and substance abuse: the saga continues . . . , 2001, Molecular Psychiatry.

[25]  T. Kikuchi,et al.  7-[3-(4-[2,3-Dimethylphenyl]piperazinyl)propoxy]-2(1H)-quinolinone (OPC-4392), a presynaptic dopamine autoreceptor agonist and postsynaptic D2 receptor antagonist. , 1988, Life sciences.

[26]  P. Leeson,et al.  L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests. , 1997, The Journal of pharmacology and experimental therapeutics.

[27]  J. Nobrega,et al.  Dopamine D2‐like sites in schizophrenia, but not in Alzheimer's, Huntington's, or control brains, for [3H]benzquinoline , 1997, Synapse.

[28]  Philip Seeman,et al.  Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine , 1991, Nature.

[29]  G A Petsko,et al.  Aromatic-aromatic interaction: a mechanism of protein structure stabilization. , 1985, Science.

[30]  P. Gmeiner,et al.  Rationally based efficacy tuning of selective dopamine d4 receptor ligands leading to the complete antagonist 2-[4-(4-chlorophenyl)piperazin-1-ylmethyl]pyrazolo[1,5-a]pyridine (FAUC 213). , 2001, Journal of medicinal chemistry.

[31]  S. Snyder,et al.  Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. , 1976, Science.

[32]  H. Weinstein,et al.  Conformational Memories and the Exploration of Biologically Relevant Peptide Conformations: An Illustration for the Gonadotropin-Releasing Hormone , 1996 .

[33]  F. Diederich,et al.  Interactions with aromatic rings in chemical and biological recognition. , 2003, Angewandte Chemie.

[34]  M. Karplus,et al.  Evaluation of comparative protein modeling by MODELLER , 1995, Proteins.

[35]  J. Feldon,et al.  FAUC 213, a highly selective dopamine D4 receptor full antagonist, exhibits atypical antipsychotic properties in behavioural and neurochemical models of schizophrenia , 2004, Psychopharmacology.

[36]  D. Helmeste,et al.  Dopamine D4 receptors. , 2000, Japanese journal of pharmacology.

[37]  Y. Sagara,et al.  The Activation of Dopamine D4 Receptors Inhibits Oxidative Stress-Induced Nerve Cell Death , 2001, The Journal of Neuroscience.

[38]  P. Seeman,et al.  Atypical Neuroleptics Have Low Affinity for Dopamine D2 Receptors or Are Selective for D4 Receptors , 1997, Neuropsychopharmacology.

[39]  T. Heffner,et al.  Substituted [(4-phenylpiperazinyl)-methyl]benzamides: selective dopamine D4 agonists. , 1997, Journal of medicinal chemistry.

[40]  P. Seeman,et al.  Low density of dopamine D4 receptors in Parkinson's, schizophrenia, and control brain striata , 1993, Synapse.